131 related articles for article (PubMed ID: 2070047)
1. Purification and characterization of factor VII 304-Gln: a variant molecule with reduced activity isolated from a clinically unaffected male.
O'Brien DP; Gale KM; Anderson JS; McVey JH; Miller GJ; Meade TW; Tuddenham EG
Blood; 1991 Jul; 78(1):132-40. PubMed ID: 2070047
[TBL] [Abstract][Full Text] [Related]
2. Impaired human tissue factor-mediated activity in blood clotting factor VIINagoya (Arg304-->Trp). Evidence that a region in the catalytic domain of factor VII is important for the association with tissue factor.
Matsushita T; Kojima T; Emi N; Takahashi I; Saito H
J Biol Chem; 1994 Mar; 269(10):7355-63. PubMed ID: 8125953
[TBL] [Abstract][Full Text] [Related]
3. Structural requirements for the interaction between tissue factor and factor VII: characterization of chymotrypsin-derived tissue factor polypeptides.
O'Brien DP; Anderson JS; Martin DM; Byfield PG; Tuddenham EG
Biochem J; 1993 May; 292 ( Pt 1)(Pt 1):7-12. PubMed ID: 8503864
[TBL] [Abstract][Full Text] [Related]
4. Surface plasmon resonance studies of the interaction between factor VII and tissue factor. Demonstration of defective tissue factor binding in a variant FVII molecule (FVII-R79Q).
O'Brien DP; Kemball-Cook G; Hutchinson AM; Martin DM; Johnson DJ; Byfield PG; Takamiya O; Tuddenham EG; McVey JH
Biochemistry; 1994 Nov; 33(47):14162-9. PubMed ID: 7947828
[TBL] [Abstract][Full Text] [Related]
5. Characterization of mild coagulation factor VII deficiency: activity and clearance of the Arg315Trp and Arg315Lys variants in the Cys310-Cys329 loop (c170s).
Furlan Freguia C; Toso R; Pollak ES; Arruda VR; Pinotti M; Bernardi F
Haematologica; 2004 Dec; 89(12):1504-9. PubMed ID: 15590402
[TBL] [Abstract][Full Text] [Related]
6. Coagulation factor VII Gln100 --> Arg. Amino acid substitution at the epidermal growth factor 2-protease domain interface results in severely reduced tissue factor binding and procoagulant function.
Kemball-Cook G; Johnson DJ; Takamiya O; Banner DW; McVey JH; Tuddenham EG
J Biol Chem; 1998 Apr; 273(14):8516-21. PubMed ID: 9525966
[TBL] [Abstract][Full Text] [Related]
7. A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates.
Toso R; Pinotti M; High KA; Pollak ES; Bernardi F
Biochem J; 2002 Apr; 363(Pt 2):411-6. PubMed ID: 11931672
[TBL] [Abstract][Full Text] [Related]
8. Factor VII mutant V154G models a zymogen-like form of factor VIIa.
Toso R; Bernardi F; Tidd T; Pinotti M; Camire RM; Marchetti G; High KA; Pollak ES
Biochem J; 2003 Feb; 369(Pt 3):563-71. PubMed ID: 12358603
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a factor VII molecule carrying a mutation in the second epidermal growth factor-like domain.
Kavlie A; Orning L; Grindflek A; Stormorken H; Prydz H
Thromb Haemost; 1998 Jun; 79(6):1136-43. PubMed ID: 9657438
[TBL] [Abstract][Full Text] [Related]
10. Characterization of porcine factor VII, X and comparison with human factor VII, X.
Chen Y; Qiao J; Tan W; Lu Y; Qin S; Zhang J; Li S; Bu H; Cheng J
Blood Cells Mol Dis; 2009; 43(1):111-8. PubMed ID: 19286401
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism (Arg353-->Gln) in coagulation factor VII gene and factor VII levels (coagulant activity, antigen and binding ability to tissue factor) in 101 healthy Japanese.
Takamiya O
Scand J Clin Lab Invest; 1995 May; 55(3):211-5. PubMed ID: 7638554
[TBL] [Abstract][Full Text] [Related]
12. Factor VIIShinjo: a dysfunctional factor VII variant homozygous for the substitution Gln for Arg at position 79.
Takamiya O; Abe S; Yoshioka A; Nakajima K; McVey JH; Tuddenham EG
Haemostasis; 1995; 25(3):89-97. PubMed ID: 7607584
[TBL] [Abstract][Full Text] [Related]
13. Two naturally occurring mutations on FVII gene (S363I-W364C) altering intrinsic catalytic activity.
Peyvandi F; De Cristofaro R; Akhavan S; Carew JA; Landolfi R; Bauer KA; Mannucci PM
Thromb Haemost; 2002 Nov; 88(5):750-5. PubMed ID: 12428089
[TBL] [Abstract][Full Text] [Related]
14. Interspecies exchange mutagenesis of the first epidermal growth factor-like domain of human factor VII.
Williamson V; Pyke A; Sridhara S; Kelley RF; Blajchman MA; Clarke BJ
J Thromb Haemost; 2005 Jun; 3(6):1250-6. PubMed ID: 15892860
[TBL] [Abstract][Full Text] [Related]
15. Expression and purification of recombinant human coagulation factor VII fused to a histidine tag using Gateway technology.
Halabian R; Fathabad ME; Masroori N; Roushandeh AM; Saki S; Amirizadeh N; Najafabadi AJ; Gharehbaghian A; Roudkenar MH
Blood Transfus; 2009 Oct; 7(4):305-12. PubMed ID: 20011642
[TBL] [Abstract][Full Text] [Related]
16. Coagulation factor VII variants resistant to inhibitory antibodies.
Branchini A; Baroni M; Pfeiffer C; Batorova A; Giansily-Blaizot M; Schved JF; Mariani G; Bernardi F; Pinotti M
Thromb Haemost; 2014 Nov; 112(5):972-80. PubMed ID: 25104096
[TBL] [Abstract][Full Text] [Related]
17. Factor VII deficiency caused by a structural variant N57D of the first epidermal growth factor domain.
Leonard BJ; Chen Q; Blajchman MA; Ofosu FA; Sridhara S; Yang D; Clarke BJ
Blood; 1998 Jan; 91(1):142-8. PubMed ID: 9414278
[TBL] [Abstract][Full Text] [Related]
18. The P303T mutation in the human factor VII (FVII) gene alters the conformational state of the enzyme and causes a severe functional deficiency.
Peyvandi F; De Cristofaro R; Garagiola I; Palla R; Akhavan S; Landolfi R; Mannucci PM
Br J Haematol; 2004 Dec; 127(5):576-84. PubMed ID: 15566361
[TBL] [Abstract][Full Text] [Related]
19. Factor VII binding to tissue factor in plasma from warfarin-treated individuals.
Takamiya O; Yoshioka A
Thromb Res; 1996 Mar; 81(6):657-63. PubMed ID: 8868516
[TBL] [Abstract][Full Text] [Related]
20. The effect of O-fucosylation on the first EGF-like domain from human blood coagulation factor VII.
Kao YH; Lee GF; Wang Y; Starovasnik MA; Kelley RF; Spellman MW; Lerner L
Biochemistry; 1999 Jun; 38(22):7097-110. PubMed ID: 10353820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
